MeiraGTx Enters into Strategic Collaboration with Janssen to Develop and Commercialize Gene Therapy Treatments for Inherited Retinal Diseases

Stock Information for MeiraGTx Holdings plc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About MeiraGTx Holdings plc

MeiraGTx Reports Second Quarter 2019 Financial Results and Provides Corporate Update
MeiraGTx Reports First Quarter 2019 Financial Results and Provides Corporate Update
MeiraGTx Announces Positive 6-Month Data from Phase 1/2 Trial of Investigational Gene Therapy AAV-RPE65 for RPE65-Deficiency
MeiraGTx Appoints Nicole Seligman to Board of Directors
MeiraGTx to Present at Bank of America Merrill Lynch Healthcare Conference
MeiraGTx Announces Upcoming Presentation on Achromatopsia Gene Therapy Candidate AAV-CNGA3 at ARVO 2019
MeiraGTx Reports Full Year 2018 Financial Results
MeiraGTx to Present at the Barclays Global Healthcare Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.